Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of treatment-resistant depression
AssigneeMapreg
InventorsMassimiliano Bianchi, Etienne Baulieu, Isabelle Villey
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for the treatment of treatment-resistant depression (TRD), comprising the administration of compounds of formula (I), which are blocked in C3 position and cannot metabolize in vivo into pregnenolone derivatives and which do not have significant affinity for steroid hormonal receptors and for all tested classical main receptors and receptors of neurotransmitters of the central nervous system.
Claims3
A method for treating treatment-resistant depression (TRD) in a subject in need thereof, comprising administering to said patient a therapeutically efficient amount of 3β-methoxy-pregna-5α-ene-20α-one of formula:
- or a pharmaceutically acceptable salt thereof;
- wherein TRD is a major depressive disorder that does not respond to, or does not evolve favorably under the influence of, adequate doses and duration of treatment with at least one anti-depressant, wherein the anti-depressant is a selective serotonin reuptake inhibitor (SSRI).
Dependencies are inferred from the claim text.